{"id":"b7758456-3892-5b72-beaa-19bc94b3d46f","stable_key":"6660bba2-4fa0-590a-bf52-9803a24bea9f:interaction-triazolam","predicate":"decreases_in_recorded_experiment","statement":"Four weeks of modafinil reduced triazolam exposure in a controlled study of 41 women; triazolam reduction exceeded the ethinyl-estradiol reduction.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"e62cea2f-62cd-53db-8e23-28d7da276e6d","mechanism_event_label":"Four weeks of modafinil reduced triazolam exposure in a controlled study of 41 women; triazolam reduction exceeded the ethinyl-estradiol reduction.","subject":{"id":"624e6a4b-f96d-5d12-8206-30d1e1715c26","slug":"modafinil","display_name":"Modafinil","entity_type_key":"drug"},"object":{"id":"32ed5d58-84d1-5157-ab86-bd443867704d","slug":"human-triazolam-exposure","display_name":"Human triazolam plasma AUC","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"e62cea2f-62cd-53db-8e23-28d7da276e6d","stable_key":"6660bba2-4fa0-590a-bf52-9803a24bea9f:interaction-triazolam-event","event_type":"experimental_observation","label":"Four weeks of modafinil reduced triazolam exposure in a controlled study of 41 women; triazolam reduction exceeded the ethinyl-estradiol reduction.","description":"A separate controlled study in 41 women found greater reduction of triazolam exposure than ethinyl-estradiol exposure after four weeks of modafinil. The authors considered intestinal first-pass induction important. A shared enzyme does not imply identical effects on all substrates. The study measured pharmacokinetics, not a contraceptive-failure rate. [Ethinyl estradiol/triazolam study](https://pubmed.ncbi.nlm.nih.gov/11823757/)","status":"provisional","compartment":null,"participants":[{"entity":{"id":"624e6a4b-f96d-5d12-8206-30d1e1715c26","slug":"modafinil","display_name":"Modafinil","entity_type_key":"drug"},"role":"tested factor","stoichiometry":null,"state_label":"Four weeks of modafinil","sequence_order":0,"notes":""},{"entity":{"id":"32ed5d58-84d1-5157-ab86-bd443867704d","slug":"human-triazolam-exposure","display_name":"Human triazolam plasma AUC","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"20bfaed7-6174-5064-a580-db3c0101a614","slug":"triazolam","display_name":"Triazolam","entity_type_key":"drug"},"role":"coadministered substrate","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"54e95ff1-4ffa-5e6f-a4cb-b47e5d2a5bda","slug":"cyp3a4","display_name":"Human cytochrome P450 3A4","entity_type_key":"protein"},"role":"proposed first-pass metabolism pathway","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary indexed abstract checked; full methods and figures not comprehensively reviewed.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Four weeks of modafinil\", \"comparator\": \"Baseline/control exposure\", \"endpoint\": \"Four weeks of modafinil reduced triazolam exposure in a controlled study of 41 women; triazolam reduction exceeded the ethinyl-estradiol reduction.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"Human pharmacokinetic trial, 41 women; drug exposure measured, not contraceptive-failure rate.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Four weeks of modafinil reduced triazolam exposure in a controlled study of 41 women; triazolam reduction exceeded the ethinyl-estradiol reduction.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. | 2002 | DOI 10.1067/mcp.2002.121217 | PMID 11823757 | https://pubmed.ncbi.nlm.nih.gov/11823757/","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference lines 128-128; exact primary location described in quoted passage where extracted.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"032511d2-a481-5e52-9219-084e0c86cf78","evidence_kind":"source_excerpt","locator":"Lines 128-128","start_line":128,"end_line":128,"excerpt":"A separate controlled study in 41 women found greater reduction of triazolam exposure than ethinyl-estradiol exposure after four weeks of modafinil. The authors considered intestinal first-pass induction important. A shared enzyme does not imply identical effects on all substrates. The study measured pharmacokinetics, not a contraceptive-failure rate. [Ethinyl estradiol/triazolam study](https://pubmed.ncbi.nlm.nih.gov/11823757/)","model_system":"Human pharmacokinetic trial, 41 women; drug exposure measured, not contraceptive-failure rate.","directness":"reported_statement","verification_status":"source_recorded","notes":"Exact excerpt of the retained AI-assisted reviewed reference; primary sources are cited in primary_references and access scope is retained. Not a verbatim quotation from a primary paper.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"17a64928-eaa2-5117-ba4f-52dcbdf9cc9e","stable_key":"import-6660bba2-4fa0-590a-bf52-9803a24bea9f","title":"Modafinil: detailed mechanisms of action (reviewed 3 October 2026)","document_type":"imported_text","citation_label":"Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication.","file_path":"","sha256":"006008cb4cfd183dd3b0846d3abc66c8ebf40cf1b6bd1f0bcdb4f4d937a8e115","revision_id":"c85b3e2e-c18a-59fc-9e79-5c375e64d119","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}